Overview
- 20 inspections across 20 sites are on record.
- 46 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-12-11.
At a glance
Inspections
20
Sites
20
Observations
46
Career since
Feb 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Human Genome Sciences Inc | 11 Dec 2023 | Human Drugs | On file |
| Catalent Indiana, LLC | 15 Nov 2023 | Biologics | View 483 → |
| Evive Biopharmaceutical (Beijing), Ltd. | 7 Jun 2023 | Human Drugs | On file |
| Suzhou Union Biopharm Co., Ltd. | 26 May 2023 | Human Drugs | On file |
| Rentschler Biopharma Inc. | 24 Mar 2023 | Human Drugs | On file |
Sites inspected
Human Genome Sciences IncRockville, United States1 insp.
Catalent Indiana, LLCBloomington, United States1 insp.
Evive Biopharmaceutical (Beijing), Ltd.Beijing, China1 insp.
Suzhou Union Biopharm Co., Ltd.Suzhou, China1 insp.
Rentschler Biopharma Inc.Milford, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Charles Y Kuo2 shared
Caryn M Mcnab2 shared
Lane V Christensen2 shared
Riley C Myers2 shared
Yuan-Chia Kuo1 shared
Hamet M Toure1 shared
Jacob G Lutz1 shared
Rafeeq A Habeeb1 shared
Alan L Truong1 shared
Andrew J Barrowcliff1 shared
Full investigator report
Get the verbatim findings behind Wendy G Tan's 46 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site